ABSTRACT
Endocrine therapy remains the primary treatment for advanced and metastatic estrogen receptor-positive (ER+) breast cancers. Patients who progress on endocrine therapy may benefit from add-on treatment targeting the PI3K/MTOR signaling pathways or by switching to chemotherapy. However, these options are only available after progression on first-line treatment with endocrine therapy. In the absence of reliable prognostic tests for advanced ER+ breast cancers, it is currently not possible to stratify patients into pertinent treatment arms at the baseline. To address this, we have developed a low-dimensional endocrine response signature (ENDORSE) model for advanced ER+ breast cancers. The ENDORSE model was developed using the baseline tumor transcriptomes and long-term survival outcomes of >800 invasive ER+ breast cancers and predicts the risk of death on endocrine therapy. ENDORSE was validated in multiple clinical trial datasets for endocrine therapy response in metastatic ER+ breast cancers and demonstrated superior predictive performance over clinical factors and published gene signatures. Our results show that ENDORSE is a reproducible and accurate prognostic model for endocrine therapy response in advanced and metastatic ER+ breast cancers.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Funding for this research was provided by the National Cancer Institute of the National Institutes of Health through the U54 grant U54CA209978. No payment or services were received by the authors or the institutions for any aspect of the submitted work.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study is exempt as it does not use Human Subjects. Only non-identifiable public datasets were used in this study.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data used in this manuscript are publicly available and listed under "Methods" section of the manuscript
